Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) EPS (Basic) (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed EPS (Basic) for 5 consecutive years, with -$0.51 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 58.54% year-over-year to -$0.51, compared with a TTM value of $0.22 through Dec 2025, up 105.98%, and an annual FY2025 reading of $0.22, up 105.98% over the prior year.
  • EPS (Basic) was -$0.51 for Q4 2025 at SAB Biotherapeutics, down from $2.38 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $2.38 in Q3 2025 and bottomed at -$3.85 in Q4 2023.
  • Average EPS (Basic) over 5 years is -$0.56, with a median of -$0.46 recorded in 2021.
  • The sharpest move saw EPS (Basic) crashed 7400.0% in 2023, then skyrocketed 312.5% in 2025.
  • Year by year, EPS (Basic) stood at -$0.41 in 2021, then surged by 56.1% to -$0.18 in 2022, then tumbled by 2038.89% to -$3.85 in 2023, then soared by 68.05% to -$1.23 in 2024, then skyrocketed by 58.54% to -$0.51 in 2025.
  • Business Quant data shows EPS (Basic) for SABS at -$0.51 in Q4 2025, $2.38 in Q3 2025, and -$1.09 in Q2 2025.